All questionsIndication: Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer2 questions · 2 sourcesEligibilityWhat is TRODELVY approved for in triple-negative breast cancer?“TRODELVY® (sacituzumab govitecan-hziy) is a Trop-2–directed antibody and topoisomerase inhibitor conjugate indicated in adult patients: Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line As a single agent for the first-line treatment of unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who are not candidates for PD-1 or PD-L1 inhibitor-based therapy In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for the first-line treatment of unresectable locally advanced or mTNBC whose tumors express PD-L1 [Combined Positive Score (CPS ≥10)] as determined by an FDA-authorized test Second Line or Later For the treatment of unresectable locally advanced or mTNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease.” (opens the source at this quote in a new tab)CopyFlagDrug namesWhat is the generic name of TRODELVY?“TRODELVY® (sacituzumab govitecan-hziy) for injection, for intravenous use” (opens the source at this quote in a new tab)CopyFlag